1	Matrix	Matrix	B-NP	NN	B-protein	3	NMOD	-1
2	metalloproteinase	metalloproteinase	I-NP	NN	I-protein	3	NMOD	-1
3	activity	activity	I-NP	NN	O	6	NMOD	0
4	and	and	O	CC	O	6	NMOD	-1
5	immunohistochemical	immunohistochemical	B-NP	JJ	O	6	NMOD	-1
6	profile	profile	I-NP	NN	O	0	ROOT	-1
7	of	of	B-PP	IN	O	6	NMOD	-1
8	matrix	matrix	B-NP	NN	B-protein	9	NMOD	-1
9	metalloproteinase-2	metalloproteinase-2	I-NP	NN	I-protein	11	NMOD	-1
10	and	and	O	CC	I-protein	11	NMOD	-1
11	-9	-9	B-NP	NN	I-protein	14	NMOD	-1
12	and	and	I-NP	CC	O	14	NMOD	-1
13	tissue	tissue	I-NP	NN	O	14	NMOD	-1
14	inhibitor	inhibitor	I-NP	NN	O	7	PMOD	0
15	of	of	B-PP	IN	O	14	NMOD	-1
16	metalloproteinase-1	metalloproteinase-1	B-NP	NN	B-protein	15	PMOD	-1
17	during	during	B-PP	IN	O	6	NMOD	-1
18	human	human	B-NP	JJ	O	21	NMOD	-1
19	dermal	dermal	I-NP	JJ	O	21	NMOD	-1
20	wound	wound	I-NP	NN	O	21	NMOD	-1
21	healing	healing	I-NP	NN	O	17	PMOD	-1
22	.	.	O	.	O	6	P	-1

1	Proteolytic	Proteolytic	B-NP	JJ	O	2	NMOD	-1
2	activity	activity	I-NP	NN	O	3	SUB	0
3	is	be	B-VP	VBZ	O	0	ROOT	-1
4	required	require	I-VP	VBN	O	3	VC	0
5	for	for	B-PP	IN	O	4	VMOD	-1
6	the	the	B-NP	DT	O	7	NMOD	-1
7	turnover	turnover	I-NP	NN	O	5	PMOD	7	turnover
8	of	of	B-PP	IN	O	7	NMOD	-1
9	the	the	B-NP	DT	O	11	NMOD	-1
10	extracellular	extracellular	I-NP	JJ	O	11	NMOD	-1
11	matrix	matrix	I-NP	NN	O	8	PMOD	-1
12	during	during	B-PP	IN	O	7	NMOD	-1
13	wound	wound	B-NP	NN	O	14	NMOD	-1
14	healing	healing	I-NP	NN	O	12	PMOD	-1
15	.	.	O	.	O	3	P	-1

1	Matrix	Matrix	B-NP	NN	B-protein	2	NMOD	-1
2	metalloproteinases	metalloproteinas	I-NP	NNS	I-protein	3	SUB	-1
3	can	can	B-VP	MD	O	0	ROOT	-1
4	collectively	collectively	I-VP	RB	O	3	VMOD	-1
5	cleave	cleave	I-VP	VB	O	3	VC	17	cleave
6	all	all	B-NP	DT	O	7	NMOD	-1
7	components	component	I-NP	NNS	O	5	OBJ	-1
8	of	of	B-PP	IN	O	7	NMOD	-1
9	the	the	B-NP	DT	O	11	NMOD	-1
10	extracellular	extracellular	I-NP	JJ	O	11	NMOD	-1
11	matrix	matrix	I-NP	NN	O	8	PMOD	-1
12	,	,	O	,	O	5	P	-1
13	with	with	B-PP	IN	O	5	VMOD	-1
14	the	the	B-NP	DT	O	17	NMOD	-1
15	endogenous	endogenous	I-NP	JJ	O	17	NMOD	-1
16	tissue	tissue	I-NP	NN	O	17	NMOD	-1
17	inhibitor	inhibitor	I-NP	NN	O	13	PMOD	0
18	of	of	B-PP	IN	O	17	NMOD	-1
19	metalloproteinase-1	metalloproteinase-1	B-NP	NN	B-protein	18	PMOD	-1
20	regulating	regulate	B-VP	VBG	O	17	NMOD	16	regulating
21	their	their	B-NP	PRP$	O	22	NMOD	-1
22	activity	activity	I-NP	NN	O	20	OBJ	0
23	.	.	O	.	O	3	P	-1

1	Breast	Breast	B-NP	NN	O	2	NMOD	-1
2	tissue	tissue	I-NP	NN	O	22	SUB	-1
3	taken	take	B-VP	VBN	O	2	NMOD	-1
4	at	at	B-PP	IN	O	3	VMOD	-1
5	varying	vary	B-VP	VBG	O	4	PMOD	-1
6	postoperative	postoperative	B-NP	JJ	O	7	NMOD	-1
7	times	time	I-NP	NNS	O	5	OBJ	-1
8	(	(	O	(	O	11	DEP	-1
9	n=	n=	B-NP	NN	O	11	DEP	-1
10	92	92	I-NP	CD	O	9	NMOD	-1
11	)	)	O	)	O	7	NMOD	-1
12	or	or	O	CC	O	4	PMOD	-1
13	during	during	B-PP	IN	O	4	PMOD	-1
14	surgery	surgery	B-NP	NN	O	13	PMOD	0
15	(	(	O	(	O	20	DEP	-1
16	controls	control	B-NP	NNS	O	20	DEP	0
17	,	,	O	,	O	20	P	-1
18	n=	n=	B-NP	NN	O	20	DEP	-1
19	17	17	I-NP	CD	O	18	NMOD	-1
20	)	)	O	)	O	14	NMOD	-1
21	,	,	O	,	O	2	P	-1
22	was	be	B-VP	VBD	O	0	ROOT	-1
23	used	use	I-VP	VBN	O	22	VC	0
24	to	to	B-VP	TO	O	25	VMOD	-1
25	investigate	investigate	I-VP	VB	O	23	VMOD	-1
26	the	the	B-NP	DT	O	30	NMOD	-1
27	temporal	temporal	I-NP	JJ	O	30	NMOD	-1
28	and	and	I-NP	CC	O	30	NMOD	-1
29	spatial	spatial	I-NP	JJ	O	30	NMOD	-1
30	activity	activity	I-NP	NN	O	25	OBJ	0
31	of	of	B-PP	IN	O	30	NMOD	-1
32	matrix	matrix	B-NP	NN	B-protein	33	NMOD	-1
33	metalloproteinase-2	metalloproteinase-2	I-NP	NN	I-protein	35	NMOD	-1
34	and	and	O	CC	I-protein	35	NMOD	-1
35	-9	-9	B-NP	NN	I-protein	38	NMOD	-1
36	and	and	I-NP	CC	O	38	NMOD	-1
37	tissue	tissue	I-NP	NN	O	38	NMOD	-1
38	inhibitor	inhibitor	I-NP	NN	O	31	PMOD	0
39	of	of	B-PP	IN	O	38	NMOD	-1
40	metalloproteinase-1	metalloproteinase-1	B-NP	NN	B-protein	39	PMOD	-1
41	during	during	B-PP	IN	O	25	VMOD	-1
42	human	human	B-NP	JJ	O	44	NMOD	-1
43	wound	wound	I-NP	NN	O	44	NMOD	-1
44	healing	healing	I-NP	NN	O	41	PMOD	-1
45	.	.	O	.	O	22	P	-1

1	Matrix	Matrix	B-NP	NN	B-protein	3	NMOD	-1
2	metalloproteinase	metalloproteinase	I-NP	NN	I-protein	3	NMOD	-1
3	activity	activity	I-NP	NN	O	27	SUB	0
4	,	,	O	,	O	3	P	-1
5	determined	determine	B-VP	VBN	O	3	NMOD	-1
6	using	use	B-VP	VBG	O	5	VMOD	-1
7	a	a	B-NP	DT	O	11	NMOD	-1
8	quenched	quench	I-NP	VBN	O	11	NMOD	-1
9	fluorescence	fluorescence	I-NP	NN	O	11	NMOD	-1
10	substrate	substrate	I-NP	NN	O	11	NMOD	-1
11	assay	assay	I-NP	NN	O	6	OBJ	-1
12	,	,	O	,	O	3	P	-1
13	increased	increase	B-VP	VBN	O	3	NMOD	17	increased
14	during	during	B-PP	IN	O	13	VMOD	-1
15	early	early	B-NP	JJ	O	16	NMOD	-1
16	healing	healing	I-NP	NN	O	14	PMOD	-1
17	(	(	O	(	O	20	DEP	-1
18	3-8	3-8	B-NP	CD	O	19	NMOD	-1
19	weeks	week	I-NP	NNS	O	20	DEP	-1
20	)	)	O	)	O	16	NMOD	-1
21	compared	compare	B-VP	VBN	O	3	NMOD	-1
22	to	to	B-PP	TO	O	21	VMOD	-1
23	controls	control	B-NP	NNS	O	22	PMOD	0
24	,	,	O	,	O	3	P	-1
25	and	and	O	CC	O	3	VMOD	-1
26	then	then	B-VP	RB	O	27	VMOD	-1
27	decreased	decrease	I-VP	VBD	O	0	ROOT	18	decreased
28	between	between	B-PP	IN	O	27	VMOD	-1
29	24	24	B-NP	CD	O	31	AMOD	-1
30	and	and	I-NP	CC	O	31	AMOD	-1
31	36	36	I-NP	CD	O	32	NMOD	-1
32	weeks	week	I-NP	NNS	O	28	PMOD	-1
33	after	after	B-PP	IN	O	32	NMOD	-1
34	surgery	surgery	B-NP	NN	O	33	PMOD	0
35	(	(	O	(	O	32	NMOD	-1
36	p	p	B-NP	NN	O	35	ROOT	-1
37	less	less	B-ADJP	JJR	O	36	NMOD	-1
38	than	than	B-PP	IN	O	37	AMOD	-1
39	0.05	0.05	B-NP	CD	O	38	PMOD	-1
40	until	until	I-NP	IN	O	36	NMOD	-1
41	24	24	I-NP	CD	O	42	NMOD	-1
42	weeks	week	I-NP	NNS	O	45	NMOD	-1
43	,	,	O	,	O	45	P	-1
44	Mann-Whitney	Mann-Whitney	B-NP	NNP	O	45	NMOD	-1
45	U-test	U-test	I-NP	NNP	O	46	DEP	-1
46	)	)	O	)	O	40	PMOD	-1
47	.	.	O	.	O	36	P	-1

1	Immunohistochemistry	Immunohistochemistry	B-NP	NN	O	2	NMOD	-1
2	scores	score	I-NP	NNS	O	7	SUB	-1
3	for	for	B-PP	IN	O	2	NMOD	-1
4	matrix	matrix	B-NP	NN	B-protein	6	NMOD	-1
5	metalloproteinase-9	metalloproteinase-9	I-NP	NN	I-protein	6	NMOD	-1
6	expression	expression	I-NP	NN	O	3	PMOD	9	expression
7	were	be	B-VP	VBD	O	0	ROOT	-1
8	significantly	significantly	I-VP	RB	O	7	VMOD	-1
9	elevated	elevate	I-VP	VBN	O	7	VC	17	elevated
10	compared	compare	B-PP	VBN	O	9	VMOD	-1
11	to	to	B-PP	TO	O	10	PMOD	-1
12	controls	control	B-NP	NNS	O	11	PMOD	0
13	in	in	B-PP	IN	O	12	NMOD	-1
14	scar	scar	B-NP	NN	B-cell_type	16	NMOD	-1
15	endothelial	endothelial	I-NP	JJ	I-cell_type	16	NMOD	-1
16	cells	cell	I-NP	NNS	I-cell_type	18	NMOD	-1
17	and	and	O	CC	O	18	NMOD	-1
18	fibroblasts	fibroblast	B-NP	NNS	B-cell_type	13	PMOD	-1
19	from	from	B-PP	IN	O	18	NMOD	-1
20	2	2	B-NP	CD	O	19	PMOD	-1
21	until	until	I-NP	IN	O	20	NMOD	-1
22	12	12	I-NP	CD	O	25	NMOD	-1
23	and	and	I-NP	CC	O	25	NMOD	-1
24	20	20	I-NP	CD	O	25	NMOD	-1
25	weeks	week	I-NP	NNS	O	21	PMOD	-1
26	,	,	O	,	O	9	P	-1
27	respectively	respectively	B-ADVP	RB	O	9	VMOD	-1
28	.	.	O	.	O	7	P	-1

1	Matrix	Matrix	B-NP	NN	B-protein	3	NMOD	-1
2	metalloproteinase-2	metalloproteinase-2	I-NP	NN	I-protein	3	NMOD	-1
3	staining	staining	I-NP	NN	O	4	SUB	0
4	was	be	B-VP	VBD	O	0	ROOT	-1
5	observed	observe	I-VP	VBN	O	4	VC	0
6	exclusively	exclusively	B-ADVP	RB	O	7	PMOD	-1
7	in	in	B-PP	IN	O	5	VMOD	-1
8	fibroblasts	fibroblast	B-NP	NNS	B-cell_type	7	PMOD	-1
9	,	,	O	,	O	4	P	-1
10	reaching	reach	B-VP	VBG	O	4	VMOD	-1
11	maximum	maximum	B-NP	NN	O	12	NMOD	-1
12	levels	level	I-NP	NNS	O	14	NMOD	-1
13	8-12	8-12	B-NP	CD	O	14	NMOD	-1
14	weeks	week	I-NP	NNS	O	10	OBJ	-1
15	after	after	B-PP	IN	O	14	NMOD	-1
16	surgery	surgery	B-NP	NN	O	15	PMOD	0
17	,	,	O	,	O	4	P	-1
18	decreasing	decrease	B-VP	VBG	O	4	VMOD	18	decreasing
19	by	by	B-PP	IN	O	18	VMOD	-1
20	1.5	1.5	B-NP	CD	O	21	NMOD	-1
21	years	year	I-NP	NNS	O	19	PMOD	-1
22	but	but	O	CC	O	4	VMOD	-1
23	remaining	remain	B-VP	VBG	O	4	VMOD	-1
24	significantly	significantly	I-VP	RB	O	23	VMOD	-1
25	increased	increase	I-VP	VBN	O	23	VC	17	increased
26	.	.	O	.	O	4	P	-1

1	Tissue	Tissue	B-NP	NN	O	2	NMOD	-1
2	inhibitor	inhibitor	I-NP	NN	O	6	SUB	0
3	of	of	B-PP	IN	O	2	NMOD	-1
4	metalloproteinase-1	metalloproteinase-1	B-NP	NN	B-protein	5	NMOD	-1
5	staining	staining	I-NP	NN	O	3	PMOD	0
6	was	be	B-VP	VBD	O	0	ROOT	-1
7	relatively	relatively	B-ADJP	RB	O	8	AMOD	-1
8	sparse	sparse	I-ADJP	JJ	O	6	PRD	-1
9	but	but	O	CC	O	6	VMOD	-1
10	was	be	B-VP	VBD	O	6	VMOD	-1
11	significantly	significantly	I-VP	RB	O	10	VMOD	-1
12	increased	increase	I-VP	VBN	O	10	VC	17	increased
13	until	until	B-PP	IN	O	12	VMOD	-1
14	8	8	B-NP	CD	O	15	NMOD	-1
15	weeks	week	I-NP	NNS	O	13	PMOD	-1
16	after	after	B-PP	IN	O	15	NMOD	-1
17	surgery	surgery	B-NP	NN	O	16	PMOD	0
18	.	.	O	.	O	6	P	-1

1	These	These	B-NP	DT	O	2	NMOD	-1
2	results	result	I-NP	NNS	O	3	SUB	0
3	show	show	B-VP	VBP	O	0	ROOT	-1
4	that	that	B-SBAR	IN	O	3	VMOD	-1
5	matrix	matrix	B-NP	NN	B-protein	6	NMOD	-1
6	metalloproteinases	metalloproteinas	I-NP	NNS	I-protein	7	SUB	-1
7	are	be	B-VP	VBP	O	4	SBAR	-1
8	present	present	B-ADJP	JJ	O	7	PRD	9	present
9	at	at	B-PP	IN	O	8	AMOD	-1
10	elevated	elevated	B-NP	JJ	O	11	NMOD	17	elevated
11	levels	level	I-NP	NNS	O	9	PMOD	-1
12	during	during	B-PP	IN	O	8	AMOD	-1
13	early	early	B-NP	JJ	O	15	NMOD	-1
14	wound	wound	I-NP	NN	O	15	NMOD	-1
15	healing	healing	I-NP	NN	O	12	PMOD	-1
16	,	,	O	,	O	7	P	-1
17	when	when	B-ADVP	WRB	O	7	VMOD	-1
18	angiogenesis	angiogenesis	B-NP	NN	O	19	SUB	3	angiogenesis
19	occurs	occur	B-VP	VBZ	O	17	SBAR	-1
20	,	,	O	,	O	7	P	-1
21	and	and	O	CC	O	7	VMOD	-1
22	suggest	suggest	B-VP	VBP	O	7	VMOD	-1
23	that	that	B-SBAR	IN	O	22	VMOD	-1
24	matrix	matrix	B-NP	NN	B-protein	25	NMOD	-1
25	metalloproteinase-9	metalloproteinase-9	I-NP	NN	I-protein	26	SUB	-1
26	may	may	B-VP	MD	O	23	SBAR	-1
27	play	play	I-VP	VB	O	26	VC	0
28	a	a	B-NP	DT	O	30	NMOD	-1
29	significant	significant	I-NP	JJ	O	30	NMOD	-1
30	role	role	I-NP	NN	O	27	OBJ	0
31	.	.	O	.	O	3	P	-1

1	The	The	B-NP	DT	O	3	NMOD	-1
2	later	later	I-NP	JJ	O	3	NMOD	-1
3	expression	expression	I-NP	NN	O	11	SUB	9	expression
4	of	of	B-PP	IN	O	3	NMOD	-1
5	matrix	matrix	B-NP	NN	B-protein	6	NMOD	-1
6	metalloproteinase-2	metalloproteinase-2	I-NP	NN	I-protein	4	PMOD	-1
7	and	and	O	CC	I-protein	8	NMOD	-1
8	-9	-9	B-NP	CD	I-protein	6	NMOD	-1
9	in	in	B-PP	IN	O	3	NMOD	-1
10	fibroblasts	fibroblast	B-NP	NNS	B-cell_type	9	PMOD	-1
11	suggests	suggest	B-VP	VBZ	O	0	ROOT	-1
12	a	a	B-NP	DT	O	13	NMOD	-1
13	role	role	I-NP	NN	O	11	OBJ	16	role
14	in	in	B-PP	IN	O	13	NMOD	-1
15	extracellular	extracellular	B-NP	JJ	O	17	NMOD	-1
16	matrix	matrix	I-NP	NN	O	17	NMOD	-1
17	remodeling	remodeling	I-NP	NN	O	14	PMOD	7	remodeling
18	.	.	O	.	O	11	P	-1

